All

API

FDF

Price

Services

Excipients

Enquiries

Find

Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace

Market Place

Post Enquiry

Grow Your Pharma Business Digitally

Scorr-Insert

X

Find Approved Gastroenterology Drugs in Clinical Development in IRELAND

A collaboration with SCORR Marketing

All Data

Filters

refresh

×

FILTER DATA :

News Type

Company

Product Type

Deal Size

Upfront Payment

refresh

Product Type

Companies

Allergan plc

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

IRELAND Ireland

Post An Enquiry

9th Annual HPAPI Summit 2020

Participation Not Confirmed

Update your events

Allergan keeps Linzess generics out until 2029 with Teva settlement

Contact the Supplier

Lead Product(s): Linaclotide

Therapeutic Area: Gastroenterology

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Teva Pharmaceuticals

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement January 23, 2020

Details:

Pursuant to the terms of the settlement, Ironwood and Allergan will grant Teva a license to market its 145 mcg and 290 mcg generic version of LINZESS in U.S.